Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series
Montanari F, Bhagat G, Seshan V, Clark-Garvey S, Zain J, Diefenbach C, McCormick E, Conroy M, Crook M, Alobeid B, O'Connor O. Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series. Blood 2010, 116: 4151. DOI: 10.1182/blood.v116.21.4151.4151.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderECOG score 0Epstein-Barr virusEpstein-Barr virus statusECOG scoreP-PTLDAdult patientsPediatric patientsScore 0Immunosuppression taperingM-PTLDRituximab groupMedian OSEarly lesionsLymphoproliferative disordersAdvanced stage III or IVPTLD subtypesIntermediate-low-risk groupSpectrum of lymphoproliferative disordersMedian OS of patientsIntermediate-high risk groupHematopoietic stem cell transplantationWorld Health Organization classification systemStage III or IVPopulation of adult patients